logo







Home>Companies>Adaptimmune-therapeutics


Adaptimmune therapeutics

Adaptimmune therapeutics



Adaptimmune Therapeutics is a biopharmaceutical company specializing in innovative cell therapies for patients with solid tumors, utilizing a proprietary platform to develop TCR therapeutic candidates targeting various cancer types.
Sign up today to get real-time market insights on Adaptimmune therapeutics and hundreds of other pre-IPO companies



Adaptimmune therapeutics Overview

2008
Biotech
https://adaptimmune.com



Adaptimmune therapeutics Live Market Data

$00000000
$00000000




Adaptimmune therapeutics Funding Rounds



RoundDateAmount RaisedValuationInvestorsSources
Secondary Transaction - Open Market8/30/2019
IPO5/6/2015
Series A9/19/2014
Early Stage VC5/3/2010
Accelerator/Incubator7/1/2008




Adaptimmune therapeutics Investors



InvestorInvestment RoundsLead PartnerInitial InvestmentOther Notable Investments
Eight RoadsEarly Stage VCEarly Stage VC (2010-05-03)
F-Prime CapitalSeries ASeries A (2014-09-19)
New Enterprise AssociatesSeries ASeries A (2014-09-19)
Novo HoldingsSeries ASeries A (2014-09-19)
Wellington ManagementSeries ASeries A (2014-09-19)




Adaptimmune therapeutics 409a Valuations



DatePrice per shareEst. ValuationFilling
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Sign up to access Adaptimmune therapeutics data




Adaptimmune therapeutics Filings



TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign up to access Adaptimmune therapeutics data




Latest Adaptimmune therapeutics News







Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


DisclaimerAll investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.